Hereditary angioedema therapeutics currently exhibits a proliferating pipeline with 20+ therapeutic candidates.
Hereditary angioedema is a genetic disease that results in swelling under the skin, lining of guts and lungs. Symptoms of the disease usually occur in childhood, and get aggravated in teenage. The symptoms include bouts of swelling and itching, which are usual characteristics of allergy infections. The swelling occurs in various parts of the body such as throat, mouth, hands, feet, face, genitals, belly, and other parts of a body. The disease can be trigger due to stress, anxiety, injury, surgery, flu, heart or blood pressure medications. Genetic mutation is another major reason for the occurrence of HAE.
Pre-Purchase Inquiry at: https://www.pharmaproff.com/enquiry/1270
There are several acquisitions and partnerships reported in the wake of technological developments for HAE therapeutics. For instance, in 2016, Shire plc merged with Baxalta Incorporated for expansion of its portfolio of rare diseases including HAE. Moreover, Takeda Pharmaceutical Company Limited acquired Shire plc in January 2019 in order to expand its geographic footprint.
Pharming Group N.V., Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring, Ionis Pharmaceuticals Inc., and Takeda Pharmaceutical Company Limited are some of the major players involved in the development of therapeutics for HAE.
This post was originally published on Financial Sector